Clinical Trial

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 7, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is the combination of lenvatinib and pembrolizumab will overcome vascular endothelial growth factor (VEGF)-mediated immunosuppression to enhance the response of patients with locally advanced or metastatic cervical cancer.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2021-04-26; most recent amendment 2025-10-03.
Status change: Not Yet Recruiting → Recruiting 2022-02-25
Trial Details
NCT Number NCT04865887
Lead Sponsor Georgetown University
Collaborators: Merck Sharp & Dohme LLC
Conditions Cervical Cancer, Metastatic Cervical Cancer
Enrollment 35 participants
Start Date 2022-10-07
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-10-07